GlassScriptPhysician profile
Zuleima Lozada
NPI 1194350348
$1,752.12
in general payments reported to CMS, 2019-2025
17 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $772 · 2023: $183 · 2024: $47.47 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.13 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.01 | 2021-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.95 | 2021-2023 | Xifaxan |
| Madrigal Pharmaceuticals | $141.40 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $124.97 | 2025 | Voquezna |
| Celgene Corporation | $99.14 | 2021-2022 | |
| Redhill Biopharma INC. | $97.33 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $75.13 | 2021 | |
| Ironwood Pharmaceuticals, INC | $67.49 | 2022-2023 | Linzess |
| Braintree Laboratories, INC. | $48.38 | 2022 | |
| Novo Nordisk INC | $42.60 | 2024-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $37.48 | 2022 | |
| Intercept Pharmaceuticals, INC. | $24.57 | 2022 | |
| Merck Sharp & Dohme LLC | $21.41 | 2025 | Capvaxive, Gardasil 9, Vaqta |
| Janssen Biotech, INC. | $20.00 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Daiichi Sankyo INC. | $15.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zuleima Lozada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.